SCHEMBL1098547

SCHEMBL1098547

O=S(=O)(c1ccccc1)N(CCN1CCOCC1)c1sc2ccccc2c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RAB9A P51151 3/20 0.40
MAPT P10636 1/20 0.39
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 1/20 0.38
NLRP3 Q96P20 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098240 0.88 MEN1 (0.44) LMNAMEN1KMT2AMMP2MMP3
SCHEMBL1098090 0.88 MEN1 (0.44) LMNAMEN1KMT2AMMP2MMP3
SCHEMBL1099400 0.82 RET (0.40) LMNAKMT2ATRPM8ALDH1A1KDM4E
SCHEMBL1098592 0.80 TRPM8 (0.49) LMNAMMP2MMP3MMP9MMP13
SCHEMBL1098125 0.80 RAB9A (0.48) LMNAMEN1KMT2ATRPM8ALDH1A1
SCHEMBL1098003 0.79 RORC (0.41) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL1099757 0.79 LOXL2 (0.43) LMNATRPM8KDM4EUSP2
SCHEMBL1098457 0.78 NR1I2 (0.44) MEN1KMT2ATRPM8ALDH1A1SMN1; SMN2
SCHEMBL1099333 0.78 ALDH1A1 (0.42) TRPM8ALDH1A1MAPTHTR1ADRD2
SCHEMBL1099290 0.77 TRPM8 (0.41) TRPM8ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 3427/4885MEN1 1640/4885KMT2A 1231/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 3427/4885MEN1 1640/4885KMT2A 1231/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 3427/4885MEN1 1640/4885KMT2A 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.